Split History
ETFs Holding ALXN »    ALXN Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alexion Pharmaceuticals is a biopharmaceutical company focused on serving patients with certain disorders through the development and commercialization of therapeutic products. Co.'s marketed product, Soliris® is a therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria. Co. markets Strensiq® for the treatment of patients with Hypophosphatasia (HPP) and Kanuma™ for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). HPP is a genetic ultra-rare disease characterized by defective bone mineralization and LAL-D is a life threatening ultra-rare disease in which genetic mutations result in decreased activity of the Lysosomal Acid Lipase enzyme. According to our ALXN split history records, Alexion Pharmaceuticals has had 2 splits.
ALXN split history picture
Alexion Pharmaceuticals (ALXN) has 2 splits in our ALXN split history database. The first split for ALXN took place on August 25, 2008. This was a 2 for 1 split, meaning for each share of ALXN owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. ALXN's second split took place on May 23, 2011. This was a 2 for 1 split, meaning for each share of ALXN owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.

When a company such as Alexion Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the ALXN split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alexion Pharmaceuticals shares, starting with a $10,000 purchase of ALXN, presented on a split-history-adjusted basis factoring in the complete ALXN split history. ALXN split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/29/2007
End date: 05/26/2017
Start price/share: $11.80
End price/share: $97.70
Dividends collected/share: $0.00
Total return: 727.97%
Average Annual Total Return: 23.54%
Starting investment: $10,000.00
Ending investment: $82,808.70
Years: 10.00
Date Ratio
08/25/20082 for 1
05/23/20112 for 1
ALXN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

AMDA Split History
AMED Split History
AMGN Split History
AMN Split History
AMPE Split History
AMRI Split History
AMRN Split History
AMSG Split History
ANCI Split History
ANIP Split History

Yield10 Bioscience, Inc. (YTEN)
Xerox Corporation (XRX)
Waste Connections, Inc. (WCN)
Spark Energy, Inc. (SPKE)
MagneGas Corporation (MNGA)
Frontier Communications Corporation (FTR)
NeuroMetrix, Inc. (NURO)
Pain Therapeutics, Inc. (PTIE)
Rex Energy Corporation (REXX)
Rexahn Pharmaceuticals, Inc. (RNN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ALXN Insider Buying

ALXN Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.